There is a need for new treatment options for patients whose treated chronic lymphocytic leukaemia or other B-cell malignancy has relapsed, or who do not respond to existing therapies. Bruton’s tyrosine kinase, or Btk, is a target that might have potential in these diseases, as it codes for a protein involved in B-cell development.
People with a mutation in this gene develop X-linked agammaglobulinaemia type 1, an immunodeficiency that results in mature B lymphocytes not being produced. In addition, Btk is overexpressed in chronic lymphocytic leukaemia, resulting in B-cell receptor signalling being aberrantly activated.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.